{"changes":[],"country":"US","description":"Sanegene Bio makes RNAi medicines for obesity, cardiometabolic, and autoimmune diseases using the LEAD system to direct gene-silencing payloads to liver, fat, muscle, and immune cells. Silencing disease genes across multiple tissue types from a single subcutaneous injection surpasses the liver-only targeting of earlier RNAi platforms.","domain":"sanegenebio.com","employees":null,"founded":2021,"fundingTotalQuarantined":false,"githubOrg":null,"githubStars":null,"industry":"bio","investors":[],"lat":42.479262,"lng":-71.152277,"location":"Woburn, United States","name":"Sanegene Bio","rounds":[{"amountQuarantined":false,"amountUsd":110000000,"currency":"USD","date":"2025-12-01","investors":[],"leadInvestor":null,"source":{"fact":"round","publisher":"crunchbase","retrievedAt":"2026-06-16","status":"attributed","url":null},"status":"attributed","type":"series-b","url":null}],"slug":"sanegenebio-com","sources":[{"fact":"round","publisher":"crunchbase","retrievedAt":"2026-06-16","status":"attributed","url":null},{"fact":"existence","publisher":"sanegenebio.com","retrievedAt":"2026-06-16","status":"self-reported","url":"https://sanegenebio.com"},{"fact":"description","publisher":"sanegenebio.com","retrievedAt":"2026-06-16","status":"self-reported","url":"https://sanegenebio.com"}],"stage":"series-b+","techStack":["unreachable"],"totalRaisedUsd":118000000,"updatedAt":"2026-06-16"}